

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□ □□ REACH □□ (EC) 1907/2006 □□ □□

SDS Reference Number: 00735


□□ □□□□: 4/9/2014 □□ □□□□: 3/5/2025 □□ □□: 4/18/2016 □□: 1.1

□□ 1: □□□□□ □□□ □□ □□

1.1. □□□□

□□ □□
□□ □□
EC □□
CAS □□
□□ □□
□□ □□
□□ □□

: □□
: ADRENALINE BITARTRATE AR
: 200-097-1
: 51-42-3
: 00735
: Organic compound
:



□□ □□ : (-)-Epinephrine (+)-bitartrate

1.2. □□□□ □□ □□□□ □□ □□ □□ □□

□□ □□ □□
□□□□/□□□□ □□

: Laboratory chemicals, Manufacture of substances

1.3. □□□□□□□□ □□□ □□

LOBA CHEMIE PVT.LTD.
107 Wode House Road, Jehangir Villa, Colaba
400005 Mumbai
INDIA
T +91 22 6663 6663, F +91 22 6663 6699
info@lobachemie.com, www.lobachemie.com

1.4. □□□□□□

□□ □□ □□ : + 91 22 6663 6663 (9:00am - 6:00 pm)

□□ 2: □□□·□□□

2.1. □□□·□□□ □□

Regulation (EC) No.1272/2008 [CLP] □□ □□ □□

| | |
|------------------------------------|------|
| □□ □□ (□□), □□ 1 | H300 |
| □□ □□□/□□ □□□, □□ 2 | H315 |
| □□ □ □□□/□ □□□, □□ 2 | H319 |
| □□□□□□ □□ - 1 □□ □□, □□ 3, □□□□ □□ | H335 |
| □□(H) □□ □ EUH □□ □□: 16 □□ □□. | |

□□□□□, □□ □□ □ □□□□□□□
□□□ □□□□. □□□ □□□ □□□ □ □□. □□□ □□□ □□□. □□ □□ □□□ □□□.

2.2. □□□□□□□ □□□ □□□□ □□

□□ (EC) No. 1272/2008 □□ □□ □□ □□ [CLP]

□□ □□ □□□□(CLP)

:



GHS06

□□□ (CLP)

: □□

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

□□·□□ □□ (CLP) : H300 - □□□ □□□□.
 H315 - □□□ □□□ □□□.
 H319 - □□ □□ □□□ □□□.
 H335 - □□□ □□□ □□□ □□□.

□□ □□ □□(CLP) : P264 - □□ □□□ hands and forearms □(□) □□□ □□□□.
 P301+P310 - □□□□ □□ □□ □(□) □□□□.
 P302+P352 - □□□ □□□ □□□ □ □□□□.
 P304+P340 - □□□□ □□□ □□□ □□ □□□ □□□ □□ □□□ □□□ □□□□.
 P305+P351+P338 - □□ □□□□: □ □□ □□ □□□□ □□□□. □□□□ □□□ □□□ □□□□□□. □□ □□□□.

2.3. □□ □□

Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII

□□ 3: □□□□□ □□ □ □□□

3.1. □□□□

□□ □□ : □□□□□□

| □□ | □□□□ | % |
|-----------------------|-------------------------------------|-----|
| ADRENALINE BITARTRATE | CAS □□: 51-42-3 EC □□: 200-097-1 | 100 |

□□ 4: □□□□□□

4.1. □□□□ □□

□□ □□ □□ : Call a physician immediately.
 □□□□ □ : □□□ □□□ □□ □□□ □□□□ □□ □□□ □□□□□. Allow affected person to breathe fresh air. □□□ □□□□□ □□□ □□□ □□ □□□ □□□□□ □□ □□□ □□□□□. □□□□ □□ □□□□(□□)□ □□□ □□□□.

□□□ □□□□ □ : □□□ □□□ □□ □□□□. □□□□ □□/□□□ □□□□. Wash skin with plenty of water. □□□ □□□ □□□□. □□ □□□ □□□□: □□□□ □□/□□□ □□□□.

□□ □□□□ □ : □ □□ □□ □□□□ □□□□. □□□□ □□□□□□ □□□□□□. □□ □□□□. □□□□ □□/□□□ □□□□ □□ □□□ □□□□: □□□□ □□/□□□ □□□□.

□□□ □ : □□ □□□□□□. □□ □□□□/□□□ □□□ □□□□. Call a physician immediately.
 First-aid measures for first aider : □□□□ □□□□ □□□ □□ □□ □□□ □□□□ □□□.

4.2. □□ □ □□□ □□ □□□ □□ □ □□

□□ □ □□/□□ : □□□ □□□ □□□ □ □□.
 □□ □□ □ □□/□□ : □□□ □□□ □□□. □□.
 □ □□ □ □□/□□ : □□ □□ □□□ □□□. Eye irritation.
 □□ □ □□/□□ : □□□ □□□□.

4.3. □□□□ □□ □ □□ □□ □□ □□ □□

Treat symptomatically.

□□ 5: □□·□□□ □□□□

5.1. □□□ □□□

□□□ □□□ : Carbon dioxide. Dry powder. Foam. Water spray.
 □□□□ □□□ : Do not use extinguishing media containing water.

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

5.2. □□□□□□ □□ □□ □□□

- □□ : No fire hazard.
- □□ : No direct explosion hazard.
- □ □□□ □□ □□ : Toxic fumes may be released.

5.3. □□□□ □□□□ □ □□□□

- □□ : Fight fire from safe distance and protected location. Do not enter fire area without proper protective equipment, including respiratory protection.
- □□ □ □□ : Do not enter fire area without proper protective equipment, including respiratory protection. Do not attempt to take action without suitable protective equipment. □□□ □□□□□. Complete protective clothing.

□□ 6: □□□□□ □□□□

6.1. □□□ □□□□ □□ □□□ □□□□ □ □□□

- □□ : □□□ □□□ □□ □□□□ □□□ □□ □□ □□ □□. □□□□□ □□□□ □□ □□□□ □□□□□□.
- □□ □□ : Wear recommended personal protective equipment.
- □□ : Evacuate unnecessary personnel. □□□ □□ □□□ □□□ □□□ □□□ □□□ □□□. □□□/□□□/□□□ □□□/□□□□□ □ □□□ □□□□.
- □□ □□ : Do not attempt to take action without suitable protective equipment. □□□ □□ □□□□ □□□□□□. □□ □□□ □□□ □□ □□: "□□□□ □ □□□□□" □□□□□□.
- □□ : Ventilate area. Evacuate unnecessary personnel.

6.2. □□□ □□□□ □□ □□□ □□□□

□□□□ □□□□ □□□.

6.3. □□ □□ □□ □□

- : Using a clean shovel, put the material in a dry container and cover without compressing it.
- □□ : Mechanically recover the product. On land, sweep or shovel into suitable containers. Soak up spills with inert solids, such as clay or diatomaceous earth as soon as possible.
- □□ □□□□ : Dispose of materials or solid residues at an authorized site.

6.4. □□ □□ □□

For further information refer to section 13.

□□ 7: □□ □ □□□□

7.1. □□□□□□

- □ □□□□□ □□ □□ : □□□□ □□ □□□□□ □□□ □□□ □□.
- : □□ □ □□□ □□□ □□□□. Do not breathe vapours. Avoid dust formation. □□ □□ □□□ □ □□ □□□ □□□□□. □□□/□□□/□□□□/□□□□□□ □ □□□ □□□□. □□ □□□□ □□□□□.
- □□ : □ □□□ □□□ □□□ □□□, □□□□ □□□□ □□□. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. □□ □□ □ □□□ □□□ □□□□□. Always wash hands after handling the product.

7.2. □□□□ □□□ □□□ □□□ □□ □□

- □□ : Keep in a cool, well-ventilated place away from heat.
- □□ : □□□ □ □□ □□ □□□□□. □□□□ □□□ □□□□□. □□□□□ □□ □□□□□. □□□□ □ □□ □□ □□ □□□. □□□ □□□ □□□□□.
- : Store always product in container of same material as original container.

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

7.3. □□ □□ □□

□□ □□

□□ 8: □□□□ □□□□□□

8.1. □□ □□ □□

□□ □□

8.2. □□□□

□□□ □□□ □□

□□□ □□□ □□:

Ensure good ventilation of the work station.

□□ □□□

□□ □□□:

Wear recommended personal protective equipment.

□□ □□ □□ □□:



□ □ □ □ □ □ □ □

□ □□:

Chemical goggles or safety glasses

Skin protection

□□ □□:

Wear a mask

□ □□:

Protective gloves

□□□ □□

□□□ □□:

Wear appropriate mask

□□ □□ □□

□□ □□ □□:

□□□□ □□□□ □□□.

□□ 9: □□□□□ □□

9.1. □□□□ □□□□□ □□□ □□ □□

□□□ □□

: □□

□□

: White to greyish white.

□□

: Crystalline powder.

□□□

: 333.3 g/mol

□□

: Odourless.

□□ □□

: □□□□

□□□

: 155 °C

□□□

: □□□□

□□ □□□□ □□□ □□

: □□□□

□□□

: □□□

□□ □□□

: □□□□

□□ □□□

: □□□□

□□□

: □□□□

□□□□ □□

: □□□□

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

| | | |
|---|---|--------------------------|
| □□ □□ | : | □□□□ |
| pH | : | 2.8 – 4 |
| pH □□□□ □□ | : | 1 % |
| □□(□□□) | : | □□□□ |
| □□□ | : | □: Soluble in cold water |
| Partition coefficient n-octanol/water (Log Kow) | : | □□□□ |
| □□□ | : | □□□□ |
| 50°C□□□□ □□□ | : | □□□□ |
| □□ | : | □□□□ |
| □□ | : | □□□□ |
| 20°C□□□□ □□ □□ □□ | : | □□□□ |
| Particle size | : | □□□□ |

9.2. □□□□□□□□

□□ □□ □□

□□ □□ : 0.6 g/cm³

□□ 10: □□□□ □□□□

10.1. □□□

The product is non-reactive under normal conditions of use, storage and transport.

10.2. □□□□□□

Stable under normal conditions.

10.3. □□□□□□□□

No dangerous reactions known under normal conditions of use.

10.4. □□□□□□□□

□□□□.

10.5. □□□□□□□□

□□ □□

10.6. □□□□□□□□□□

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

□□ 11: □□□□ □□ □□

11.1. □□ (EC) No 1272/2008 □□□□, □□□□ □□□□ □□ □□

| | | |
|----------------|---|----------------|
| □□ □□ (□□) | : | □□□□ □□□□. |
| □□ □□ (□□) | : | □□□□ □□ |
| □□ □□ (□□) | : | □□□□ □□ |
| □□ □□□□ □□ □□□ | : | □□□□ □□□□ □□□. |
| | | pH: 2.8 – 4 |

ADRENALINE BITARTRATE (51-42-3)

| | |
|-----------------|-------------------|
| pH | 2.8 – 4 |
| □□ □□ □□ □□ □□□ | : □□ □□ □□□□ □□□. |
| | pH: 2.8 – 4 |

ADRENALINE BITARTRATE (51-42-3)

| | |
|----------------|-----------|
| pH | 2.8 – 4 |
| □□□□ □□ □□ □□□ | : □□□□ □□ |
| □□□□ □□□□ | : □□□□ □□ |

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

□□□ : □□□□ □□
□□□□ : □□□□ □□
□□ □□□□ □□ (1□ □□) : □□□ □□□ □□□ □ □□.

| ADRENALINE BITARTRATE (51-42-3) | |
|---------------------------------|---------------------|
| □□ □□□□ □□ (1□ □□) | □□□□ □□□□ □□□ □ □□. |

□□ □□□□ □□ (□□ □□) : □□□□ □□
□□ □□□ : □□□□ □□

| ADRENALINE BITARTRATE AR (51-42-3) | |
|------------------------------------|------|
| □□(□□□) | □□□□ |

| ADRENALINE BITARTRATE (51-42-3) | |
|---------------------------------|------|
| □□(□□□) | □□□□ |

11.2. □□ □□ □□

□ □□ □□□□
□□ □□□ □□□ □□□ □□ □□ □□ □□ : □□□ □□□□

□□ 12: □□□ □□□ □□

12.1. □□

□□□ - □□ : The product is not considered harmful to aquatic organisms nor to cause long-term adverse effects in the environment.
□□ □□□□ □□□ : □□□□ □□
□□ □□□□ □□□ : □□□□ □□

12.2. □□□ □□□□

| ADRENALINE BITARTRATE AR (51-42-3) | |
|------------------------------------|----------|
| □□□ □ □□□ | □□ □□ □□ |

| ADRENALINE BITARTRATE (51-42-3) | |
|---------------------------------|----------|
| □□□ □ □□□ | □□ □□ □□ |

12.3. □□ □□□

□□ □□

12.4. □□ □□□

□□ □□

12.5. PBT □ vPvB □□ □□

□□ □□

12.6. □□□ □□ □□

□□ □□

12.7. □□ □□ □□

□□ □□

□□ 13: □□□ □□□□

13.1. □□□ □□□

□□ □□(□□□) : Disposal must be done according to official regulations.

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

| | |
|------------------------------|---|
| □□ □□□ | : Dispose of contents/container in accordance with licensed collector's sorting instructions. |
| □□ □□ □□ □□ | : Disposal must be done according to official regulations. |
| □□/□□ □□ □□□□ | : □□, □□, □□ □/□□ □□ □□□□ □□ □□ □□□□ □□ □□ □ □□□□ □□ □□□□□. |
| | Disposal must be done according to official regulations. |
| □□ □□ | : Do not re-use empty containers. |
| Ecological waste information | : Hazardous waste due to toxicity. |

□□ **14:** □□□ □□□ □□

ADR / IMDG / IATA / ADN / RID □□ □□

14.1. UN □□ □□ **ID** □□

| | |
|--------------|-----------|
| UN-□□ (ADR) | : UN 2811 |
| UN-□□ (IMDG) | : UN 2811 |
| UN-□□ (IATA) | : UN 2811 |
| UN-□□ (ADN) | : UN 2811 |
| UN-□□ (RID) | : UN 2811 |

14.2. UN □□ □□□

| | |
|----------------------|--|
| □□ □□□ (ADR) | : □□ □□, □□□, □□ □□□ □□□ □□ □ |
| □□ □□□ (IMDG) | : TOXIC SOLID, ORGANIC, N.O.S. |
| □□ □□□ (IATA) | : Toxic solid, organic, n.o.s. |
| □□ □□□ (ADN) | : □□ □□, □□□, □□ □□□ □□□ □□ □ |
| □□ □□□ (RID) | : □□ □□, □□□, □□ □□□ □□□ □□ □ |
| □□ □□ □□ (ADR) (ADR) | : UN 2811 □□ □□, □□□, □□ □□□ □□□ □□ □ (ADRENALINE BITARTRATE), 6.1, III, (E) |
| □□ □□ □□ (IMDG) | : UN 2811 TOXIC SOLID, ORGANIC, N.O.S., 6.1, III |
| □□ □□ □□ (IATA) | : UN 2811 Toxic solid, organic, n.o.s. (ADRENALINE BITARTRATE), 6.1, III |
| □□ □□ □□ (ADN) | : UN 2811 □□ □□, □□□, □□ □□□ □□□ □□ □, 6.1, III |
| □□ □□ □□ (RID) | : UN 2811 □□ □□, □□□, □□ □□□ □□□ □□ □, 6.1, III |

14.3. □□□□□ □□□ □□

ADR

| | |
|--------------------|-------|
| □□□□□ □□□ □□ (ADR) | : 6.1 |
| □□ □□ (ADR) | : 6.1 |
| : | : |



IMDG

| | |
|---------------------|-------|
| □□□□□ □□□ □□ (IMDG) | : 6.1 |
| □□ □□ (IMDG) | : 6.1 |
| : | : |



IATA

| | |
|---------------------|-------|
| □□□□□ □□□ □□ (IATA) | : 6.1 |
| □□ □□ (IATA) | : 6.1 |
| : | : |



ADN

| | |
|--------------------|-------|
| □□□□□ □□□ □□ (ADN) | : 6.1 |
| □□ □□ (ADN) | : 6.1 |

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□



RID

□□□□□ □□□ □□ (RID) : 6.1
 □□ □□ (RID) : 6.1



14.4. □□□□


□□ □□ (ADR) : III
 □□ □□(IMDG) : III
 □□ □□ (IATA) : III
 □□ □□(ADN) : III
 □□ □□(RID) : III

14.5. □□ □□□

□□□ □□ : □□□
 □□□□□□ : □□□
 EmS-No. (□□) : F-A
 EmS-No. (□□) : S-A
 □ □□ □□□□ : □□ □□ □□ □□

14.6. □□□□ □□ □□ □□□□

□□ □□ : T2
 □□ □□ (ADR) : 274, 614
 □□ □□(ADR) : 5kg
 □□□(ADR) : E1
 □□ □□(ADR) : P002, IBC08, LP02, R001
 □□ □□ (ADR) : B3
 □□ □□ □□ □□ □□(ADR) : MP10
 □□□ □□ □ □□ □□□□ □□ (ADR) : T1
 □□□ □□ □ □□ □□□□ □□ □□ (ADR) : TP33
 □□ □□(ADR) : SGAH, L4BH
 □□ □□ □□(ADR) : TU15, TE19
 □□ □□□□ □□ : AT
 □□ □□(ADR) : 2
 □□ □□ □□ □□ - □□ □□(ADR) : VC1, VC2, AP7
 □□ □□ □□ □□ - □□□, □□ □ □□□(ADR) : CV13, CV28
 □□ □□ □□ □□ - □□□(ADR) : S9
 □□ □□ □□(Kemler □□) : 60
 Orange plates (□□□□□□) :



□□ □□ □□ (ADR) : E
 EAC □□ : 2X

□□ □□

□□ □□ (IMDG) : 223, 274
 □□ □□(IMDG) : 5 kg
 □□□(IMDG) : E1
 □□ □□ (IMDG) : P002
 IBC □□ □□(IMDG) : IBC08
 IBC □□ □□ (IMDG) : B3

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

□□ □□ (IMDG) : T1
□□ □□ □□ (IMDG) : TP33
□□ □□ (IMDG) : A
□□□ □□□□ (IMDG) : Toxic if swallowed, by skin contact or by inhalation.
MFAG-□□ : 154

□□ □□
PCA □□ □□(IATA) : E1
PCA □□ □□(IATA) : Y645
PCA □□ □□ □□ □□□(IATA) : 10kg
PCA □□ □□(IATA) : 670
PCA □□ □□□(IATA) : 100kg
CAO □□ □□(IATA) : 677
CAO □□ □□□(IATA) : 200kg
□□ □□(IATA) : A3, A5
ERG □□(IATA) : 6L

□□ □□ □□
□□ □□(ADN) : T2
□□ □□(ADN) : 274, 614, 802
□□□(ADN) : 5 kg
□□□(ADN) : E1
□□□□(ADN) : T
□□ □□(ADN) : PP, EP
□□ □□/□□□ □□(ADN) : 0

□□ □□
□□ □□(RID) : T2
□□ □□(RID) : 274, 614
□□ □□(RID) : 5kg
□□□(RID) : E1
□□ □□ (RID) : P002, IBC08, LP02, R001
□□ □□ (RID) : B3
□□ □□ □□ □□ □□(RID) : MP10
□□□ □□ □□ □□□□ □□ (RID) : T1
□□□ □□ □□ □□□□ □□ □□ (RID) : TP33
RID □□□ □□ □□(RID) : SGAH, L4BH
RID □□□ □□ □□(RID) : TU15
□□ □□(RID) : 2
□□ □□ □□ □□ - □□ □□(RID) : VC1, VC2, AP7
□□ □□ □□ □□ -□□, □□ □□ □□(RID) : CW13, CW28, CW31
□□ □□□ : CE11
□□□ □□ □□ (RID) : 60

14.7. □□□□□□(IMO) □□ □□ □□ □□

□□□□

□□ 15: □□ □□□□

15.1. □□, □□ □□□□ □□□□ □□□□ □□ □□ □□/□□

EU □□

REACH □□□ XVII (□□ □□)

REACH □□□ XVII □□□□ □□

REACH □□□ XIV (□□ □□)

REACH □□□ XIV (□□ □□) □□□□ □□

REACH □□ □□ □□ (SVHC)

REACH □□ □□ □□ □□ □□ □□□□ □□

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

PIC □□ (□□□□□□)

PIC □□□ □□□□ □□ (□□ EU 649/2012)

POP □□ (□□□ □□ □□□□)

POP □□□ □□□□ □□ (□□ EU 2019/1021)

Ozone Regulation (2024/590)

Not listed on the Ozone Depletion list (Regulation EU 2024/590)

□□□□ □□(428/2009)

Contains no substance subject to the COUNCIL REGULATION (EC) for the control of dual-use items

□□ □□□□ □□ (2019/1148)

□□□ □□□□ □□(□□ □□□□□ □□ □ □□□ □□ □□ EU 2019/1148) □□ □□ □□ □□ □□

□□ □□□□ □□ (273/2004)

□□ □□□□ □□□ □□□ □□□ □□□ □□(□□ □ □□□□ □□□ □□ □□□ □□□ □□ □□□ □□ □□ EC 273/2004)

□□ □□

□□

VOC ordinance (ChemVOCFarbV) :

WGK : WGK 3, □□ □□ □□□ (Classification according to AwSV; ID □□ 865).
□□□□ □□ □□ (ChemVerbotsV) : This product is subject to ChemVerbotsV Annex 2 Entry 1. The following requirements must be observed: authorization requirement (according to § 6 paragraph 1 sentence 1), basic requirements for carrying out the delivery (according to § 8 paragraph 1, 3 and 4), identification and documentation (according to § 9 paragraph 1 to 3) and exclusion of the shipping route (according to § 10).
□□ □□ □□(12. BImSchV) : □□ □□ □□(12. BImSchV) □□ □□ □□

□□□□

SZW-lijst van kankerverwekkende stoffen : □□□ □□□□ □□□□□.
SZW-lijst van mutagene stoffen : □□□ □□□□ □□□□□.
SZW-lijst van reprotoxische stoffen – Borstvoeding : □□□ □□□□ □□□□□.
SZW-lijst van reprotoxische stoffen – Vruchtbaarheid : □□□ □□□□ □□□□□.
SZW-lijst van reprotoxische stoffen – Ontwikkeling : □□□ □□□□ □□□□□.

□□□

□□□ □□ □□ : 18□ □□ □□□ □□ □□□ □□□□□

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

□□□

□□□ □□ □□

: Act of 25 February 2011 on chemical substances and their mixtures (J. o L. No. 63, item 322 as amended; consolidated text J. o L. 2019, item 1225).
 Act of 14 December 2012 on waste (J. o L. 2013, item 322 as amended; consolidated text J. o L. 2020, item 797).
 The announcement of Marshal of the Sejm of the Republic of Poland dated 19 October 2016 concerning the consolidated text announcement of the decree on the management of packaging and packaging waste (J. o L. 2016, item 1863 as amended).
 Decree of the Minister of Environment of 14 December 2014 on the catalogue of waste (J. o L. 2014, item 1923).
 Act of 19 August 2011 on the Carriage of Dangerous Goods (J. o L. 2011 No. 227, item 1367 as amended; consolidated text J. o L. 2020, item 154).
 Regulation of the Minister of Family, Labour and Social Policy of 12 June 2018 on the highest permissible concentration and intensity of noxious agents for health at work environment (J. o L. item 1286 as amended).
 The announcement of Minister of Health dated 9 September 2016 concerning the consolidated text announcement of the decree of the Minister of Health of 30 December 2004 on health and safety at work related to exposure to chemical agents at work (J. o L. of 16 September 2016, item 1488)
 Regulation of the Minister of Health of 2 February 2011 on tests and measurements of the noxious agents for health at work environment (J. o L. No. 33, item 166 as amended).
 Regulation of the Minister of Environment of 9 December 2003 on particularly hazardous substances to the environment (J. o L. No. 217, item 2141).
 ADR Agreement: Government Statement of 13 March 2023 on the entry into force of amendments to Annexes A and B to the Agreement concerning the International Carriage of Dangerous Goods by Road (ADR), signed in Geneva on 30 September 1957 (J. o. L. 2023, item 891)

15.2. □□ □□ □□□ □□

No chemical safety assessment has been carried out

□□ 16: □ □□ □□□□

| □□ □ □□□□: | |
|------------|---|
| ACGIH | American Conference of Government Industrial Hygienists |
| ADN | European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways |
| ADR | European Agreement concerning the International Carriage of Dangerous Goods by Road |
| ATE | Acute Toxicity Estimate |
| BCF | Bioconcentration factor |
| BLV | □□ □□ □ |
| BOD | Biochemical oxygen demand (BOD) |
| CAS □□ | □□□□ □□ □□ □□(CAS) |
| CLP | Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008 |
| COD | □□□ □□ □□□ |
| CSA | □□ □□ □□□ □□ |
| DMEL | Derived Minimal Effect level |
| DNEL | □□ □□□ □□ |
| EC □□ | □□ □□□ □□ |
| EC50 | Median effective concentration |
| ED | □□□ □□□□ |
| EN | □□ □□ |
| EWC | European waste catalogue |

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□□ REACH □□ (EC) 1907/2006 □□ □□

| □□ □ □□□□□: | |
|-------------|--|
| IARC | International Agency for Research on Cancer |
| IATA | International Air Transport Association |
| IMDG | International Maritime Dangerous Goods |
| LC50 | Median lethal concentration |
| LD50 | Median lethal dose |
| LOAEL | Lowest Observed Adverse Effect Level |
| Log Kow | Partition coefficient n-octanol/water (Log Kow) |
| Log Pow | Partition coefficient n-octanol/water (Log Pow) |
| MAK | maximum workplace concentration |
| NOAEC | No-Observed Adverse Effect Concentration |
| NOAEL | No-Observed Adverse Effect Level |
| NOEC | No-Observed Effect Concentration |
| N.O.S. | Not Otherwise Specified |
| OECD | Organisation for Economic Co-operation and Development |
| OEL | □□□ □□ □□ |
| OSHA | Occupational Safety & Health Administration |
| PBT | Persistent Bioaccumulative Toxic |
| PNEC | □□ □□□ □□ |
| PPE | □□ □□□ |
| RID | Regulations concerning the International Carriage of Dangerous Goods by Rail |
| SDS | □□□□□□□□ |
| STP | Sewage treatment plant |
| TF | □□□ □□ |
| ThOD | Theoretical oxygen demand (ThOD) |
| TLM | Median Tolerance Limit |
| TWA | Time Weighted Average |
| COV | Volatile Organic Compounds |
| vPvB | Very Persistent and Very Bioaccumulative |
| UFI | □□ □□ □□□ |

| □H□ □ EUH□ □□: | |
|----------------------|----------------------------------|
| □□ □□ 1 (□□) | □□ □□ (□□), □□ 1 |
| □ □□□ 2 | □□ □ □□□/□ □□□, □□ 2 |
| □□ □□□□ □□ (1□ □□) 3 | □□□□□□ □□ - 1□ □□, □□ 3, □□□□ □□ |
| □□ □□□ 2 | □□ □□□□/□□ □□□□, □□ 2 |
| H300 | □□□ □□□□. |
| H315 | □□□ □□□ □□□. |
| H319 | □□ □□ □□□ □□□. |
| H335 | □□□ □□□ □□□ □ □□. |

ADRENALINE BITARTRATE AR

□□□□□□□□

□□ (EU) 2020/878 □□ □□ REACH □□ (EC) 1907/2006 □□

□□□□□□□(SDS), EU

□ □□□ □□ □□□ □□ □□□ □□ □□□ □□, □□ □ □□ □□□ □□ □□□□ □□ □□□□. □□□□ □□ □□□ □□□ □□□ □□ □□ □□□□ □□□□.